3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
70
Colorectal Neoplasms
18
Carcinoma, Hepatocellular
17
Rectal Neoplasms
13
Colonic Neoplasms
13
Neoplasm Metastasis
12
Esophageal Neoplasms
11
Neoplasms
9
Gallbladder Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Bile Duct Neoplasms
7
Liver Neoplasms
6
Adenocarcinoma Of Esophagus
5
Breast Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Salivary Gland Neoplasms
3
Prostatic Neoplasms
3
Gastrointestinal Neoplasms
3
Esthesioneuroblastoma, Olfactory
3
Esophageal Squamous Cell Carcinoma
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Pancreatic Intraductal Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Carcinoma, Renal Cell
2
Biliary Tract Neoplasms
2
Anus Neoplasms
2
Adenomatous Polyposis Coli
2
Interventions
Gemcitabine
6
Fluorouracil
5
Leucovorin
4
Irinotecan
3
Albumin-Bound Paclitaxel
3
pembrolizumab
2
irinotecan sucrosofate
2
Oxaliplatin
2
4-fluorobenzoyl-TN-14003
2
zolbetuximab
1
regorafenib
1
olaparib
1
ibrutinib
1
beta-D-glucosylisophosphoramide mustard
1
adavosertib
1
Tetrahydrouridine
1
Telemedicine
1
Taxes
1
Practice Guidelines as Topic
1
Paclitaxel
1
PEGPH20
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Decitabine
1
Counseling
1
Cisplatin
1
Capecitabine
1
BKT140
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Pancreatic Adenocarcinoma
×
Erlotinib Hydrochloride
×
Gastrointestinal
×
Clear all
NCT01729481
2017-07-19
ML22774
Ludwig-Maximilians - University of Munich
Phase 2
Unknown
150 enrolled